Profit surges at Pfizer during second quarter

Profit surges at Pfizer during second quarter


Pfizer is reporting a second-quarter profit surge, though the drugmaker says weakening currencies in Europe and Asia could nick revenue ahead.



from Biotech News
Share:

FDA nimmt Antrag für Cladribin-Tabletten als potenzielle Behandlung für schubförmige MS zur Prüfung an

FDA nimmt Antrag für Cladribin-Tabletten als potenzielle Behandlung für schubförmige MS zur Prüfung an


Merck hat bekannt gegeben, dass die US-amerikanische Zulassungsbehörde FDA den erneut eingereichten Antrag auf Marktzulassung für Cladribin-Tabletten als potenzielle Behandlung für Patienten mit schubförmiger Multipler Sklerose (MS) zur Prüfung angenommen hat. „Wir freuen uns, dass die FDA die Einre...

from bionity.com News | Ein Übersichtsbeitrag über Goldankauf in Berlin, Germany.
Share:

Profit surges at Pfizer in 2Q on lower taxes, drug sales

Profit surges at Pfizer in 2Q on lower taxes, drug sales


In this Nov. 23, 2015, file photo, the Pfizer logo is displayed at world headquarters in New York. Pfizer Inc. on Tuesday, July 31, 2018, reported second-quarter earnings of $3.87 billion.



from Biotech News
Share:

Antibiotics are Powerful Tools for Fighting Infections and Sepsis, but Must be Used Appropriately

Antibiotics are Powerful Tools for Fighting Infections and Sepsis, but Must be Used Appropriately


The Centers for Disease Control and Prevention wants patients and families to know that antibiotics are the most powerful tools we have to fight life-threatening infections, like those that can lead to sepsis. Sepsis is the body's extreme response to an infection.



from Biotech News
Share:

China widens vaccine scandal probe, vows tough penalties

China widens vaccine scandal probe, vows tough penalties


China's drug watchdog published details on Tuesday of an investigation into a second firm found to have made inferior vaccines, after cabinet vowed tough penalties and fines over a vaccine safety scandal that has sparked widespread anger. A worker takes vaccine vials to inspect at the workshop of vaccine maker Wuhan Institute of Biological Products in Wuhan, Hubei province, China May 26, 2010.



from Biotech News
Share:

What is K2? Synthetic marijuana leads to more than 300 overdoses in...

What is K2? Synthetic marijuana leads to more than 300 overdoses in...


The state's Office of the Chief Medical Examiner "heavily suspects" some deaths with unconfirmed causes of death are related to K2 overdose. Officials have performed toxicology reports and results are pending.



from Biotech News
Share:

Novartis erhält EU-Zulassung für Migräne-Mittel Aimovig

Novartis erhält EU-Zulassung für Migräne-Mittel Aimovig


(dpA-afx) Der schweizerische Pharmakonzern Novartis kann das Migräne-Medikament Aimovig (erenumab) nun auch in der Europäischen Union auf den Markt bringen. Die EU-Kommission habe den Wirkstoff zur Migräne-Prävention zugelassen, teilte Novartis am Montagabend mit. Der Schritt kommt nicht überraschen...

from bionity.com News | Ein Übersichtsbeitrag über Goldankauf in Berlin, Germany.
Share:

35,406 Shares in SPDR S&P Biotech Etf (Xbi) Acquired by Simplex Trading LLC

35,406 Shares in SPDR S&P Biotech Etf (Xbi) Acquired by Simplex Trading LLC


Simplex Trading LLC acquired a new position in shares of SPDR S&P Biotech ETF in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 35,406 shares of the exchange traded fund's stock, valued at approximately $3,370,000.



from Biotech News
Share:

Viele offene Fragen im Skandal um verunreinigte Blutdrucksenker

Viele offene Fragen im Skandal um verunreinigte Blutdrucksenker


(dpa) Vor drei Wochen wurde bekannt, dass viele Bluthochdruckmittel, die auf dem Wirkstoff Valsartan basieren, mit einem potenziell krebserregenden Stoff verunreinigt sind. Doch darüber hinaus sind viele Fragen offen: Weder die deutschen Landesbehörden noch die Hersteller haben bislang Daten zur Dos...

from bionity.com News | Ein Übersichtsbeitrag über Goldankauf in Berlin, Germany.
Share:

11,974 Shares in IDEXX Laboratories, Inc. (IDXX) Acquired by Eqis Capital Management Inc.

11,974 Shares in IDEXX Laboratories, Inc. (IDXX) Acquired by Eqis Capital Management Inc.


Eqis Capital Management Inc. bought a new stake in IDEXX Laboratories, Inc. during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 11,974 shares of the company's stock, valued at approximately $2,610,000.



from Biotech News
Share:

Probiotika gegen Kinderunterernährung

Probiotika gegen Kinderunterernährung


image description
Ein vom Consejo Superior de Investigaciones Científicas (CSIC) geleitetes Projekt arbeitet an der Entwicklung probiotischer Pflanzennahrung für Kinder mit Unterernährungsproblemen. Es ist eine internationale Zusammenarbeit, an der neben Spanien auch Forschungszentren aus Argentinien, Kolumbien, Guat...

from bionity.com News | Ein Übersichtsbeitrag über Goldankauf in Berlin, Germany.
Share:

Natural Health Trends (NHTC) and Central Garden & Pet (CENT) Head to Head Analysis

Natural Health Trends (NHTC) and Central Garden & Pet (CENT) Head to Head Analysis


Natural Health Trends and Central Garden & Pet are both consumer discretionary companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, dividends and profitability. Central Garden & Pet has a consensus price target of $47.67, suggesting a potential upside of 11.92%.



from Biotech News
Share:

Indivior says generic's appeal gets granted-in-part motion on preliminary injunction

Indivior says generic's appeal gets granted-in-part motion on preliminary injunction


Indivior Plc on Monday said a U.S. Court granted-in-part a motion to expedite a rival's appeal of a preliminary injunction that blocked the sale of copycat versions of the British drugmaker's bestselling opioid addiction treatment in the United States. Earlier this month, a court had granted a preliminary injunction, preventing generic rival Dr. Reddy's Laboratories from re-launching its copycat version until the patent litigation is concluded or until the company prevails on an appeal of the injunction.



from Biotech News
Share:

Aurinia Pharmaceuticals (AUPH) vs. Fortress Biotech (FBIO) Financial Contrast

Aurinia Pharmaceuticals (AUPH) vs. Fortress Biotech (FBIO) Financial Contrast


Aurinia Pharmaceuticals and Fortress Biotech are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, profitability, institutional ownership, risk, analyst recommendations, earnings and valuation. Aurinia Pharmaceuticals presently has a consensus target price of $12.17, indicating a potential upside of 117.65%.



from Biotech News
Share:

Finanzen: Aufsichtspflicht : Aufsichtspflichten von Eltern

Kinder machen manchmal Unfug – Eltern haften für die Schäden aber nur, sofern sie ihre Aufsichtspflicht verletzt haben.

from Finanztip Feed
Supported by Video Collection
Share:

Hong Kong could become biotech listing hub, says BeiGene boss

Hong Kong could become biotech listing hub, says BeiGene boss


Hong Kong could become biotech listing hub, says BeiGene boss as Chinese drug maker gears up for US$1 billion flotation The cancer treatment firm is the first to seek a secondary listing in the city since the bourse overhauled its rules in a bid to attract big technology companies Hong Kong's stock exchange could become a hub for mainland biotechnology firms thanks to a sweeping reform of listing rules, said the boss of BeiGene, the first such company to take advantage of the new regime for a secondary listing.



from Biotech News
Share:

Krebsarznei sorgt bei Merck & Co für Schwung

Krebsarznei sorgt bei Merck & Co für Schwung


(dpa-AFX) Gute Geschäfte mit seinem Krebsmittel Keytruda halten den Pharmakonzern Merck & Co in der Überholspur. Das US-Unternehmen erhöhte zur Vorlage seiner Zahlen für das zweite Quartal abermals die Ergebnisprognose. Demnach soll der bereinigte Gewinn je Aktie nun im Vergleich zum Vorjahreszeitra...

from bionity.com News | Ein Übersichtsbeitrag über Goldankauf in Berlin, Germany.
Share:

Auch deutsche Pharmakonzerne beugen sich Trump

Auch deutsche Pharmakonzerne beugen sich Trump


(dpa) Nach harscher Kritik von Präsident Donald Trump an hohen Medikamentenpreisen in den USA machen jetzt auch deutsche Pharmakonzerne Zugeständnisse. Sie folgen einer Reihe von Branchen-Schwergewichten, die auf Preiserhöhungen in Amerika verzichten, um Trump nicht zu provozieren. Was für Patienten...

from bionity.com News | Ein Übersichtsbeitrag über Goldankauf in Berlin, Germany.
Share:

Impfstoff-Skandal in China: Polizei beantragt 18 Haftbefehle

Impfstoff-Skandal in China: Polizei beantragt 18 Haftbefehle


(dpa) Im Skandal um minderwertige Impfstoffe in China hat die Polizei Haftbefehle gegen 18 Verdächtige beantragt. Wie die staatliche Nachrichtenagentur Xinhua am Sonntag berichtete, handelt es sich dabei ausschließlich um Mitarbeiter des Unternehmens Changsheng Life Sciences, darunter auch die Vorst...

from bionity.com News | Ein Übersichtsbeitrag über Goldankauf in Berlin, Germany.
Share:

Probiotika gegen Kinderunterernährung

Probiotika gegen Kinderunterernährung


image description
Ein vom Consejo Superior de Investigaciones Científicas (CSIC) geleitetes Projekt arbeitet an der Entwicklung probiotischer Pflanzennahrung für Kinder mit Unterernährungsproblemen. Es ist eine internationale Zusammenarbeit, an der neben Spanien auch Forschungszentren aus Argentinien, Kolumbien, Guat...

from bionity.com News | Ein Übersichtsbeitrag über Goldankauf in Berlin, Germany.
Share:

Whittier Trust Co. Has $12.52 Million Stake in Gilead Sciences, Inc.

Whittier Trust Co. Has $12.52 Million Stake in Gilead Sciences, Inc.


Whittier Trust Co. lessened its holdings in shares of Gilead Sciences, Inc. by 1.2% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission.



from Biotech News
Share:

Numerous lawsuits claim baby powder causes ovarian cancer, so is it safe or not?

Numerous lawsuits claim baby powder causes ovarian cancer, so is it safe or not?


Mary Krpan, who is presently going through chemotherapy for ovarian cancer, is photographed at her home in Hamilton, Ont. on Friday, July 27, 2018.



from Biotech News
Share:

Wirkstoff weckt Hoffnung auf Heilung von Hepatitis E

Wirkstoff weckt Hoffnung auf Heilung von Hepatitis E


Gegen Hepatitis E gibt es bisher keine spezifische Therapie: Rund 70.000 Menschen sterben weltweit jährlich daran. Ein internationales Forscherteam hat nun in dem natürlich vorkommenden Stoff Silvestrol einen möglichen Wirkstoff gegen das Virus gefunden. Sowohl in Zellkultur als auch im Mausmodell h...

from bionity.com News | Ein Übersichtsbeitrag über Goldankauf in Berlin, Germany.
Share:

Neuartiges Antibiotikum auf Ackerunkraut entdeckt

Neuartiges Antibiotikum auf Ackerunkraut entdeckt


image description
Forschende haben in einem SNF-Projekt neuartige, antibiotisch wirksame chemische Substanzen entdeckt – an einem für diese Zwecke bisher kaum erforschten Ort: der Blattoberfläche eines weit verbreiteten Ackerunkrauts. Die nun publizierten Ergebnisse zeigen, dass sich in diesem Mikrokosmos viele noch ...

from bionity.com News | Ein Übersichtsbeitrag über Goldankauf in Berlin, Germany.
Share:

Chinese police apply to arrest 18 at scandal-hit vaccine firm

Chinese police apply to arrest 18 at scandal-hit vaccine firm


Police in the northeastern Chinese city of Changchun said on Sunday they had asked prosecutors to approve the arrest of 18 people at Changsheng Bio-technology Co Ltd, a vaccine maker at the centre of a safety scandal. Calls to the company seeking comment went unanswered.



from Biotech News
Share:

Chinese police apply to arrest 18 at scandal-hit vaccine firm

Chinese police apply to arrest 18 at scandal-hit vaccine firm


People gather at the gate of Changchun Changsheng Bio-technology Co Ltd, the Chinese vaccine maker, in Changchun, China, Jul 26, 2018. BEIJING: Police in the northeastern Chinese city of Changchun said on Sunday they had asked prosecutors to approve the arrest of 18 people at Changsheng Bio-technology Co Ltd, a vaccine maker at the centre of a safety scandal.



from Biotech News
Share:

Chinese police apply to arrest 18 at scandal-hit vaccine firm

Chinese police apply to arrest 18 at scandal-hit vaccine firm


Police in the northeastern Chinese city of Changchun said on Sunday they had asked prosecutors to approve the arrest of 18 people at Changsheng Bio-technology Co Ltd, a vaccine maker at the center of a safety scandal. China has launched sweeping spot checks on vaccine makers after Changsheng was found to have falsified data and sold ineffective vaccines for children, a case that has ignited public anger.



from Biotech News
Share:

Wells Fargo & Co Increases Edwards Lifesciences (EW) Price Target to $170.00

Wells Fargo & Co Increases Edwards Lifesciences (EW) Price Target to $170.00


The firm presently has an "outperform" rating on the medical research company's stock. Wells Fargo & Co's price objective would indicate a potential upside of 19.83% from the company's current price.



from Biotech News
Share:

Whittier Trust Co. of Nevada Inc. Has $2.41 Million Holdings in SPDR S&P Biotech Etf

Whittier Trust Co. of Nevada Inc. Has $2.41 Million Holdings in SPDR S&P Biotech Etf


Whittier Trust Co. of Nevada Inc. raised its stake in shares of SPDR S&P Biotech ETF by 40.0% in the second quarter, according to its most recent 13F filing with the SEC.



from Biotech News
Share:

Arca Biopharma (ABIO) to Release Quarterly Earnings on Thursday

Arca Biopharma (ABIO) to Release Quarterly Earnings on Thursday


Arca Biopharma last released its earnings results on Tuesday, May 8th. The biopharmaceutical company reported earnings per share for the quarter, meeting the consensus estimate of .



from Biotech News
Share:

Oncolytics Biotech (ONCY) Downgraded by ValuEngine to "Hold"

Oncolytics Biotech (ONCY) Downgraded by ValuEngine to "Hold"


Separately, Zacks Investment Research cut Oncolytics Biotech from a "hold" rating to a "sell" rating in a report on Thursday, June 7th. NASDAQ ONCY opened at $4.77 on Thursday.



from Biotech News
Share:

23AndMe wants to do more than showcase your family tree

23AndMe wants to do more than showcase your family tree


The home genetics company has teamed up with pharmaceutical giant GlaxoSmithKline to design new drugs that could treat diseases like Parkinson's, among others. Given 23andMe's substantial genetic database provided by its 5 million customers, the company hopes that a partnership with GSK could provide the necessary data to develop effective therapies.



from Biotech News
Share:

Seattle Genetics, Inc. (SGEN) Expected to Announce Quarterly Sales of $149.75 Million

Seattle Genetics, Inc. (SGEN) Expected to Announce Quarterly Sales of $149.75 Million


Equities research analysts predict that Seattle Genetics, Inc. will report sales of $149.75 million for the current fiscal quarter, Zacks Investment Research reports. Six analysts have issued estimates for Seattle Genetics' earnings.



from Biotech News
Share:

Correction: Earns-Alexion Pharmaceuticals story

Correction: Earns-Alexion Pharmaceuticals story


Alexion Pharmaceuticals Inc. on Thursday reported a second-quarter loss of $457.4 million, after reporting a profit in the same period a year earlier.



from Biotech News
Share:

Bayer Hits Back at New Netflix Medical Device Documentary

Bayer Hits Back at New Netflix Medical Device Documentary


Bayer AG disputed accusations in a new Netflix documentary that claims medical device makers and the U.S. Food and Drug Administration placed profits before patient safety. The company, in a statement released Thursday night, said the documentary "The Bleeding Edge," which debuted on the streaming site on Friday, lacks scientific support and cherry-picked facts to present an inaccurate and misleading picture of Bayer's permanent birth control device Essure, one of the products spotlighted in the film.



from Biotech News
Share:

3 of the Biggest IPO Winners of 2018

3 of the Biggest IPO Winners of 2018


In 2018's first six months, 120 companies were taken public, raising more than $35 billion in equity, according to The Wall Street Journal . The company went public on Feb. 8 at $11.25 per share.



from Biotech News
Share:

Merck beats views on sales jumps for cancer drugs, vaccines

Merck beats views on sales jumps for cancer drugs, vaccines


This May 1, 2018 file photo shows Merck corporate headquarters in Kenilworth, N.J. Merck & Co. on Friday, July 27 reported second-quarter profit of $1.71 billion.



from Biotech News
Share:

Merck sales grow globally

Merck sales grow globally


The Kenilworth, New Jersey, drugmaker on Friday posted a second-quarter profit of $1.71 billion, or 63 cents per share.



from Biotech News
Share:

Vertex and Alexion Are Schooling Big Biotech

Vertex and Alexion Are Schooling Big Biotech


It's been a pretty miserable year for biotech's biggest names, rife with disappointments and sluggish share-price performance. Not so for two middlewights of the industry: Vertex Pharmaceuticals Inc. and Alexion Pharmaceuticals Inc. Strong earnings reports from Vertex Wednesday afternoon and Alexion Thursday morning capped off what's been a string of largely positive news for the companies, whose market values clock in at a not-quite-top-tier $45 billion and $30 billion, respectively.



from Biotech News
Share:

UPDATE 2-Bristol-Myers cancer ruling hits shares after strong earnings

UPDATE 2-Bristol-Myers cancer ruling hits shares after strong earnings


FILE PHOTO: Logo of global biopharmaceutical company Bristol-Myers Squibb is pictured at the headquarters in Le Passage, near Agen, France, March 29, 2018. REUTERS/Regis Duvignau/File Photo The company said it was notified on Wednesday of the pending negative decision for the use of Opdivo and Yervoy as combination therapy for first-line kidney cancer by the Committee for Medicinal Products for Human Use , part of the European Medicines Agency.



from Biotech News
Share:

Alzheimer's drug gives researchers hope even as it raises more questions Source: Cox Media Group

Alzheimer's drug gives researchers hope even as it raises more questions Source: Cox Media Group


A day after the drug company Biogen reported promising results on an experimental Alzheimer's drug, experts were optimistic that researchers may be turning the corner on the mind-robbing disease after years of failure. Cambridge, Mass-based Biogen and Tokyo-based Eisai Co.



from Biotech News
Share:

New HudsonAlpha building is 'next step' for Alabama biotech industry

New HudsonAlpha building is 'next step' for Alabama biotech industry


More sweeping views across a high, open lobby. More glass and natural light. More tall columns of Alabama pine.



from Biotech News
Share:

Analysis: Viral content - vaccine scandal test Beijing's grip on information control

Analysis: Viral content - vaccine scandal test Beijing's grip on information control


A Chinese vaccine scandal has laid bare a new challenge Beijing faces in its long-running battle for information control: blogs and online articles by independent writers capable of unleashing a storm of public fury. People gather at the gate of Changchun Changsheng Bio-technology Co Ltd, the Chinese vaccine maker, in Changchun, China July 26, 2018.



from Biotech News
Share:

Contrasting Natural Health Trends

Contrasting Natural Health Trends


Natural Health Trends and Central Garden & Pet are both consumer discretionary companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, institutional ownership, risk, valuation and dividends. Natural Health Trends pays an annual dividend of $0.56 per share and has a dividend yield of 2.3%.



from Biotech News
Share:

Biotech CEO Testifies Before the Joint Economic Committee on Pro-Growth Policies

Biotech CEO Testifies Before the Joint Economic Committee on Pro-Growth Policies


Jul 25, 2018--Rachel King, co-Founder and Chief Executive Officer of GlycoMimetics, Inc., testified today on behalf of the Biotechnology Innovation Organization before the Joint Economic Committee. King discussed the need to build on the success of the JOBS Act, FDASIA's "breakthrough therapies" designation, as well as policies that provide tax relief and strengthen patent protections.



from Biotech News
Share:

Finanzen: Aktien-Ratgeber : In Aktien anlegen

Mit Erfolg in Aktien zu investieren, ist gar nicht so schwer. Wie die Börsen ticken und warum Aktien auf lange Sicht nicht so riskant sind, wie viele denken.

from Finanztip Feed
Supported by Video Collection
Share:

UPDATE 2-GSK bets $300 mln on genetics as CEO plays down break-up talk

UPDATE 2-GSK bets $300 mln on genetics as CEO plays down break-up talk


GlaxoSmithKline aims to turbo-charge its drug discovery engine with a big bet on genetics as its CEO on Wednesday played down the idea of hiving off consumer healthcare, which is a source of cash generation for such R&D investment. FILE PHOTO: The GlaxoSmithKline logo is seen on top of GSK Asia House in Singapore, March 21, 2018.



from Biotech News
Share:

Finanzen: Rufnummernmitnahme : Rufnummernmitnahme

Wenn Sie den Mobilfunkanbieter wechseln, können Sie Ihre Rufnummer mitnehmen. Es gibt ein paar Dinge zu beachten.

from Finanztip Feed
Supported by Video Collection
Share:

Finanzen: Gold kaufen : Gold kaufen

Wer sich gegen Krisen wappnen will, kann physisches Gold kaufen. Vergleichen Sie Preise auf Online-Portalen. Die Schwankungen im Portfolio lassen sich auch über Wertpapiere (ETCs) mindern.

from Finanztip Feed
Supported by Video Collection
Share:

Pharma giant GSK announces major restructuring drive to cut 400m in costs

Pharma giant GSK announces major restructuring drive to cut 400m in costs


GlaxoSmithKline has announced a major restructuring programme that will see the company slash 400 million in annual costs in an effort to bolster research spending. The pharmaceuticals giant, which has plants at Irvine in Ayrshire and Montrose, said on Wednesday that the savings would be delivered primarily through "supply chain optimisation" and a cut in administrative costs.



from Biotech News
Share:

Finanzen: Gold und Goldpreis : In Gold anlegen

Gold gilt oft als sicherer Hafen. Doch schwankt stärker als eine Anlage in weltweit gestreute Aktien. Es dient, wenn überhaupt, nur als Beimischung.

from Finanztip Feed
Supported by Video Collection
Share:

Finanzen: Widerspruch bei Lebensversicherung : Lebensversicherung widerrufen

War die Widerrufsbelehrung falsch, können Sie Ihre alte Lebensversicherung rückabwickeln. So bekommen Sie die Beiträge plus Zinsen wieder.

from Finanztip Feed
Supported by Video Collection
Share:

Finanzen: Steuersoftware : Steuerprogramm

Wer bei seiner Steuererklärung nichts zu verschenken hat, benutzt am besten eine Steuersoftware. Gute Programme gibt es schon für kleines Geld.

from Finanztip Feed
Supported by Video Collection
Share:

Drug maker GSK invests in gene profiling services

Drug maker GSK invests in gene profiling services


Drug maker GlaxoSmithKline says second-quarter revenue was 7.3 billion pounds , up 4 percent when discounting currency shifts, amid a promising performance of a new shingles treatment. Sales of the shingles treatment Shingrix made 167 million pounds, and the company increased its forecast for 2018 sales of the drug to as much as 650 million pounds.



from Biotech News
Share:

Over 200 salmonella infections linked to backyard chickens, CDC warns Source: Cox Media Group

Over 200 salmonella infections linked to backyard chickens, CDC warns Source: Cox Media Group


At least 212 cases of salmonella infections have been linked to contact with backyard chickens, the Centers for Disease Control and Prevention warns. Just over 25 percent of the reported cases are children younger than five years old, the CDC said Monday.



from Biotech News
Share:

EU top court rules new breeding techniques count as GMOs

EU top court rules new breeding techniques count as GMOs


The European Union's top court has ruled that a series of new biotechnology breeding techniques should fall under the EU's rules of safety checks and labeling restricting genetically modified organisms. Biotech companies have been working on a new generation of technologies to change genetic material in plants or animals, and it had long been debated whether they need to match the EU's rules limiting genetic modification, which are much stricter than in the United States.



from Biotech News
Share:

Chinese Parents, Pharma Industry Worried Sick After Latest Vaccine Scandal

Chinese Parents, Pharma Industry Worried Sick After Latest Vaccine Scandal


A nurse prepares a vaccine to be given to a child in a hospital in Beijing, China, April 13, 2016. Blog posts represent the views of CFR fellows and staff and not those of CFR, which takes no institutional positions.



from Biotech News
Share:

Handout photo from Bourn Hall Fertility Clinic of (left to right)...

Handout photo from Bourn Hall Fertility Clinic of (left to right)...


Handout photo from Bourn Hall Fertility Clinic of gynaecologist Patrick Steptoe, embryologist Jean Purdy and physiologist Robert Edwards at the birth of Louise Brown on 25th July 1978 A remarkable archive kept by the mother of the world's first test tube baby has been revealed to mark the 40th anniversary of her birth. Lesley Brown's collection of letters, photographs, films, newspapers, magazines and mementos from trips abroad can now be viewed in Bristol.



from Biotech News
Share:

Finanzen: Billigstrom : Billiger Strom

Versorger locken Kunden mit sehr günstigen Stromtarifen. Mit manchen machen die Anbieter offenkundig Verlust. Kunden müssen dann mit starken Preiserhöhungen rechnen.

from Finanztip Feed
Supported by Video Collection
Share:

Finanzen: Splittingtabelle : Ehegattensplitting

Verheiratete oder verpartnerte Steuerzahler können ihre Zahlungen an den Fiskus deutlich reduzieren.

from Finanztip Feed
Supported by Video Collection
Share:

U.S. to narrow opioid bribe case against Insys founder, others

U.S. to narrow opioid bribe case against Insys founder, others


U.S. prosecutors on Tuesday said they will narrow a case against several former Insys Therapeutics Inc executives accused of bribing doctors to prescribe a potent opioid after a federal judge questioned the scope of the indictment charging them. FILE PHOTO: The billionaire founder of Insys Therapeutics Inc. John Kapoor, exits the federal court house after a bail hearing in Phoenix, Arizona , U.S., October 27, 2017.



from Biotech News
Share:

Finanzen: Stromvergleich : Stromvergleich

Nutzen Sie unseren verbraucherfreundlichen Tarifrechner, um ganz einfach zu einem günstigen und fairen Stromanbieter zu wechseln.

from Finanztip Feed
Supported by Video Collection
Share:

Finanzen: Stromanbieter wechseln : Stromanbieter-Vergleich

Etliche Haushalte in Deutschland zahlen deutlich zu viel für ihren Strom. Dabei ist ein günstiger Anbieter schnell gefunden – und der Wechsel ganz einfach.

from Finanztip Feed
Supported by Video Collection
Share:

Volkskrankheit Rheumatoide Arthritis

Volkskrankheit Rheumatoide Arthritis


image description
Rheumatoide Arthritis ist eine Volkskrankheit - und oft werden die schmerzenden Gelenke mit kortisonhaltigen Medikamenten behandelt. Dabei reichen die Nebenwirkungen von Knochenschwund bis Diabetes. Eine Forschergruppe um Prof. Jan Tuckermann von der Universität Ulm hat nun molekulare Mechanismen de...

from bionity.com News | Ein Übersichtsbeitrag über Goldankauf in Berlin, Germany.
Share:

Pfizer to build new facility, add 450 jobs in Michigan

Pfizer to build new facility, add 450 jobs in Michigan


Drugmaker Pfizer Inc. plans to expand manufacturing in Michigan and add 450 jobs under an incentives deal approved Tuesday by the state's economic development arm. The company is expected to spend $465 million building a new facility in Portage near Kalamazoo, with production starting in 2024.



from Biotech News
Share:

Finanzen: Gaspreis Zusammensetzung : Gaspreise

Gut die Hälfte des Gaspreises ist fix. Einfluss haben Sie auf die andere Hälfte: die Liefer- und Vertriebskosten. Wechseln Sie jetzt den Anbieter!

from Finanztip Feed
Supported by Video Collection
Share:

Material and healthcare sectors lift ASX as investor confidence returns

Material and healthcare sectors lift ASX as investor confidence returns


The S&P/ASX 200 index closed 38.2 points, or 0.6 per cent higher, at 6265.8 lifting from a big loss on Monday. BHP Billiton led the market gains as it rose 1.7 per cent to $33.01 while Rio Tinto closed 1.3 per cent higher at $80.90.



from Biotech News
Share:

Principal Financial Group Inc. Acquires 23,652 Shares of Edwards Lifesciences Corp

Principal Financial Group Inc. Acquires 23,652 Shares of Edwards Lifesciences Corp


Principal Financial Group Inc. grew its holdings in shares of Edwards Lifesciences Corp by 5.4% during the 1st quarter, Holdings Channel reports. The firm owned 461,654 shares of the medical research company's stock after buying an additional 23,652 shares during the period.



from Biotech News
Share:

Biogen beats estimates on Spinraza sales, raises forecast

Biogen beats estimates on Spinraza sales, raises forecast


Biogen Inc reported a 9 percent rise in quarterly revenue on Tuesday, helped by demand for its spinal muscular atrophy drug Spinraza. FILE PHOTO: A sign marks a Biogen facility in Cambridge, Massachusetts, U.S. January 26, 2017.



from Biotech News
Share:

UPDATE 1-Eli Lilly spins off animal health unit, second quarter beats

UPDATE 1-Eli Lilly spins off animal health unit, second quarter beats


Eli Lilly and Co on Tuesday said it would spin off its Elanco animal health business into a publicly-traded company and posted better-than-expected quarterly profit helped by demand for its diabetes drugs Trulicity and Humalog. FILE PHOTO: The logo and ticker for Eli Lilly and Co.



from Biotech News
Share:

Eli Lilly tops 2Q earnings, guidance expectations

Eli Lilly tops 2Q earnings, guidance expectations


Eli Lilly & Co. reported a jump in second-quarter sales along with upbeat guidance, pushing shares higher in early trading.



from Biotech News
Share:

NIH awards professor 2nd $1.3M grant for lung disease study

NIH awards professor 2nd $1.3M grant for lung disease study


The Daily Press reported Monday that the chair of the pharmaceutical sciences department, Neelam Azad, received her second $1.3 million independent investigator award from the National Institutes of Health. The goal is to use traditional molecular biology techniques, along with less conventional methods, to look at markers for pulmonary fibrosis.



from Biotech News
Share:

No Tribal Immunity in PTO Proceedings, Federal Circuit Rules

No Tribal Immunity in PTO Proceedings, Federal Circuit Rules


So ruled the U.S. Court of Appeals for the Federal Circuit on July 20, bringing to an end-absent Supreme Court review-a controversy that has roiled the patent world for much of the last year. A unanimous panel affirmed a Patent Trial and Appeal Board decision to proceed with inter partes review proceedings of Allergan Inc.'s patents on a dry eye treatment.



from Biotech News
Share:

Doctors: Woman likely spread Ebola a year after infection

Doctors: Woman likely spread Ebola a year after infection


This undated colorized transmission electron micrograph image made available by the Centers for Disease Control and Prevention shows an Ebola virion. A Liberian woman who probably caught Ebola in 2014 may have infected three relatives a year after she first fell sick, doctors reported in a study published Monday, July 23, 2018.



from Biotech News
Share:

FDA staff raises efficacy doubts on GSK's lung disease treatment

FDA staff raises efficacy doubts on GSK's lung disease treatment


U.S. Food and Drug Administration staff reviewers have raised doubts over the effectiveness of GlaxoSmithKline Plc's drug Nucala in treating a disease that limits airflow to the lungs. FILE PHOTO: The GlaxoSmithKline logo is seen on top of GSK Asia House in Singapore, March 21, 2018.



from Biotech News
Share:

Mehr Nachweise multiresistenter Erreger - Therapieoptionen schwinden

Mehr Nachweise multiresistenter Erreger - Therapieoptionen schwinden


(dpa) - Bei einer wachsenden Zahl von Krankenhauspatienten in Deutschland werden Keime mit Resistenzen gegen wichtige Reserve-Antibiotika nachgewiesen. Das geht aus Daten des Nationalen Referenzzentrums für gramnegative Krankenhauserreger (NRZ) der Ruhr-Universität Bochum hervor, die das Robert Koch...

from bionity.com News | Ein Übersichtsbeitrag über Goldankauf in Berlin, Germany.
Share:

Unternehmen stoppen Antibiotika-Entwicklung

Unternehmen stoppen Antibiotika-Entwicklung


Während sich multiresistente Keime zunehmend verbreiten, ziehen sich mehr und mehr Pharmakonzerne aus der Antibiotika-Forschung zurück. Jüngstes Beispiel ist Novartis. Alternative Entwicklungs- und Finanzierungsmodelle sind für das wenig lukrative Geschäft mit antiinfektiven Wirkstoffen gefragt. Das...

from bionity.com News | Ein Übersichtsbeitrag über Goldankauf in Berlin, Germany.
Share:

Omeros Corporation Initiates Sales of OMIDRIA in Europe

Omeros Corporation Initiates Sales of OMIDRIA in Europe


Jul 23, 2018--Omeros Corporation today announced initial sales of OMIDRIA A 1%/0.3% in Europe. OMIDRIA, approved and commercially available in the U.S., is also approved in the European Union for use in cataract and lens replacement surgery to maintain mydriasis , prevent miosis , and to reduce postoperative eye pain.



from Biotech News
Share:

Thinking of paying for financial advice? Start by considering these questions

Thinking of paying for financial advice? Start by considering these questions


Image source: Getty Images. Investors focused on the healthcare sector seem to be getting scared -- and it's not even Halloween yet.



from Biotech News
Share:

China vaccine scandal ripples through domestic market, threatens global push

China vaccine scandal ripples through domestic market, threatens global push


A vaccine scandal in China, which has hit a nerve in the country and prompted quick reactions from leaders in Beijing, is sending ripples across the wider domestic drug market while threatening to dent Chinese ambitions to play a larger global role. Chinese Premier Li Keqiang speaks at the China-EU Business Roundtable held at the Great Hall of the People in Beijing, China, Monday, July 16, 2018.



from Biotech News
Share:

Idera Pharmaceuticals (IDRA) & Oncobiologics (ONS) Critical Contrast

Idera Pharmaceuticals (IDRA) & Oncobiologics (ONS) Critical Contrast


Idera Pharmaceuticals and Oncobiologics are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations. 42.5% of Idera Pharmaceuticals shares are owned by institutional investors.



from Biotech News
Share:

Finanzen: Private Veräußerungsgeschäfte : Private Veräußerungsgeschäfte

Als privates Veräußerungsgeschäft kann der Verkauf einer Immobilie innerhalb der Spekulationsfrist von zehn Jahren steuerpflichtig sein.

from Finanztip Feed
Supported by Video Collection
Share:

Finanzen: Smartphone-Banken : Smartphone-Banken

Einige Direktbanken optimieren ihre Girokonten für das Banking über Smartphones. Sie setzen auf neue digitale Funktionen.

from Finanztip Feed
Supported by Video Collection
Share:

Finanzen: Überschussbeteiligung in der Lebensversicherung : Überschussbeteiligung Lebensversicherung



from Finanztip Feed
Supported by Video Collection
Share:

Impfskandal erschüttert China - Regierungschef fordert Bestrafung

Impfskandal erschüttert China - Regierungschef fordert Bestrafung


(dpa) - Ein neuer Skandal um schadhafte Impfstoffe hat in China für große Aufregung gesorgt. Nach Enthüllungen über regelwidrige und unsachgemäße Produktion von Tollwut-Impfstoffen bei einem Hersteller rief Chinas Ministerpräsident Li Keqiang zu einer sofortigen Untersuchung und Bestrafung der Veran...

from bionity.com News | Ein Übersichtsbeitrag über Goldankauf in Berlin, Germany.
Share:

Brokerages Set $8.00 Target Price for Moleculin Biotech Inc

Brokerages Set $8.00 Target Price for Moleculin Biotech Inc


Moleculin Biotech Inc has been assigned an average broker rating score of 1.00 from the one analysts that provide coverage for the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy recommendation.



from Biotech News
Share:

Finanzen: Faktorverfahren Steuerklasse : Steuerklasse 4 mit Faktor

Ehepaare oder eingetragene Lebenspartner können neben den Steuerklassen III/V oder IV/IV auch die Kombination IV/IV mit Faktor wählen. Für wen sich dieses Faktorverfahren lohnt, lesen Sie hier.

from Finanztip Feed
Supported by Video Collection
Share:

Malloy launches lead poisoning awareness campaign

Malloy launches lead poisoning awareness campaign


The campaign, consisting of billboards, advertisements on social media and public service announcements, will be funded by a grand from the federal Centers for Disease Control and Prevention.



from Biotech News
Share:

Amgen, Inc. (AMGN) Holdings Cut by Heritage Investors Management Corp

Amgen, Inc. (AMGN) Holdings Cut by Heritage Investors Management Corp


Heritage Investors Management Corp lowered its stake in shares of Amgen, Inc. by 1.1% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 105,136 shares of the medical research company's stock after selling 1,212 shares during the period.



from Biotech News
Share:

Antikörper verringern Nebenwirkungen von Antibiotika in der Lunge

Antikörper verringern Nebenwirkungen von Antibiotika in der Lunge


Wissenschaftler der Charité – Universitätsmedizin Berlin haben nachgewiesen, dass Antibiotika das Abwehrsystem der Lunge schwächen können und damit das Risiko einer Lungenentzündung erhöhen. Die Ergebnisse weisen darauf hin, dass sich dieses Risiko durch die medikamentöse Gabe von Antikörpern verrin...

from bionity.com News | Ein Übersichtsbeitrag über Goldankauf in Berlin, Germany.
Share:

Aradigm Co. (ARDM) Receives Average Recommendation of a oeHolda from Brokerages

Aradigm Co. (ARDM) Receives Average Recommendation of a oeHolda from Brokerages


Complete the form below to receive the latest headlines and analysts' recommendations for Aradigm with our free daily email newsletter: Aradigm Co. has been given a consensus broker rating score of 3.00 from the one analysts that provide coverage for the company, Zacks Investment Research reports.



from Biotech News
Share:

Eli Lilly And Co (LLY) Shares Sold by Tiaa Fsb

Eli Lilly And Co (LLY) Shares Sold by Tiaa Fsb


Tiaa Fsb decreased its holdings in Eli Lilly And Co by 13.2% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 64,412 shares of the company's stock after selling 9,806 shares during the quarter.



from Biotech News
Share:

Trinity Biotech (TRIB) and Achieve Life Sciences (ACHV) Head to Head Contrast

Trinity Biotech (TRIB) and Achieve Life Sciences (ACHV) Head to Head Contrast


Trinity Biotech and Achieve Life Sciences are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends. Trinity Biotech has a beta of 1.31, indicating that its share price is 31% more volatile than the S&P 500.



from Biotech News
Share:

Bayer to Stop Selling Essure in U.S.

Bayer to Stop Selling Essure in U.S.


Company says it is discontinuing sales of birth-control device 'for business reasons, and not for any safety or efficacy concerns' Bayer AG will stop selling its Essure birth-control device in the U.S. after this year due to declining sales, the company said Friday.



from Biotech News
Share:

Canaccord Previews Biotech Catalysts In The Second Half: Neurological Drugs In Focus

Canaccord Previews Biotech Catalysts In The Second Half: Neurological Drugs In Focus


The biotech space represents a gold mine of opportunity for investors to multiply their investment returns, courtesy of the volatility generated by market-moving catalysts. In a note this week, Canaccord Genuity analyst Sumant Kulkarni presented a list of key catalysts for companies in his coverage universe, with those involving neurological disorder drugs dominating the list.



from Biotech News
Share:

Pharmaceutical Companies Seek Stability in Trump Drug Cost Fight

Pharmaceutical Companies Seek Stability in Trump Drug Cost Fight


Several major pharmaceutical companies lowered their spending on lobbyists in the second quarter of 2018, a time of uncertainty as President Donald Trump's administration continued its campaign to lower drug costs for consumers. Pharmaceutical Research and Manufacturers of America spent $5.54 million between April and June, down 7.7 percent from the same period last year, according to disclosures released by the federal government on Friday.



from Biotech News
Share:

UK Competition Appeal Tribunal Overturns Abuse of Dominance Fines on Pharmaceutical Companies

UK Competition Appeal Tribunal Overturns Abuse of Dominance Fines on Pharmaceutical Companies


The UK's Competition Appeal Tribunal has overturned a finding of abuse of dominance against Pfizer Inc. and Flynn Pharma Ltd. The ruling followed appeals by those companies against a 2016 Competition & Markets Authority decision which held the two companies had abused their respective dominant positions as the manufacturer and distributor of phenytoin sodium capsules, used to treat epilepsy. The CMA had concluded that the parties had increased the price of the drug to the National Health Service by up to 2,600% and that such pricing was excessive and abusive.



from Biotech News
Share:

UPDATE 1-GlaxoSmithKline considers splitting up the group - FT

UPDATE 1-GlaxoSmithKline considers splitting up the group - FT


FILE PHOTO: The GlaxoSmithKline logo is seen on top of GSK Asia House in Singapore, March 21, 2018. REUTERS/Loriene Perera/File Photo GSK Chairman Philip Hampton has been in discussions with the group's biggest shareholders about the creation of a standalone pharma and vaccines company in the medium term, the FT reported, citing sources.



from Biotech News
Share:

Swiss, German drugmakers join U.S. price freeze

Swiss, German drugmakers join U.S. price freeze


European drugmakers Roche, Bayer and Merck KGaA became the latest companies to freeze prices in the United States following criticism by the Trump administration of the cost of medicine. FILE PHOTO: The logo of Swiss pharmaceutical company Roche is pictured on the company's headquarters in Basel February 4, 2009.



from Biotech News
Share:

U.S. custodian bank State Street to buy investment firm Charles River

U.S. custodian bank State Street to buy investment firm Charles River


FILE PHOTO: The logo and trading symbol of financial services company State Street are displayed on a screen on the floor of the New York Stock Exchange in New York, U.S., March 8, 2017. REUTERS/Brendan McDermid The acquisition gives State Street a service platform through which clients would be able to get in and out of funds as well as access investment and portfolio data.



from Biotech News
Share:

's Daily Biotech Pulse: PTC To Buy Agilis, Zynerba To...

's Daily Biotech Pulse: PTC To Buy Agilis, Zynerba To...


PTC Therapeutics, Inc. announced an agreement to buy Agilis Biotherapeutics, which is developing a gene therapy platform for rare monogenic diseases affecting the central nervous system, for an upfront payment of $50 million in cash and about $150 million in PTC common stock. In addition, Agilis stands to receive up to $745 million in milestone payments.



from Biotech News
Share:

Another famous Triangle true-crime case -- the Eric Miller murder -- comes to TV Friday

Another famous Triangle true-crime case -- the Eric Miller murder -- comes to TV Friday


The murder of the young, Raleigh-based pediatric AIDS researcher Eric Miller is the subject of a new Investigation Discovery show airing Friday. The story is familiar to those who lived in the Raleigh area in 2000, around the time of Miller's death.



from Biotech News
Share:

Davis R M Inc. Sells 74,483 Shares of Hologic, Inc.

Davis R M Inc. Sells 74,483 Shares of Hologic, Inc.


Davis R M Inc. decreased its holdings in Hologic, Inc. by 9.2% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 738,174 shares of the medical equipment provider's stock after selling 74,483 shares during the period.



from Biotech News
Share:

SPDR S&P Biotech Etf (Xbi) Shares Bought by David R. Rahn & Associates Inc.

SPDR S&P Biotech Etf (Xbi) Shares Bought by David R. Rahn & Associates Inc.


David R. Rahn & Associates Inc. raised its holdings in shares of SPDR S&P Biotech ETF by 11.4% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission . The institutional investor owned 20,624 shares of the exchange traded fund's stock after acquiring an additional 2,109 shares during the quarter.



from Biotech News
Share:

Finanzen: Mieten oder Kaufen einer Immobilie : Mieten oder kaufen

Die eigene Immobilie ist noch immer der Traum vieler Menschen. Nicht immer ist der Kauf einer Wohnung oder eines Hauses die richtige Entscheidung.

from Finanztip Feed
Supported by Video Collection
Share:

Finanzen: Ratgeber Baufinanzierung : Baufinanzierung

Wer optimal finanzieren möchte, braucht günstige Zinsen und ein vernünftiges Konzept. Wir zeigen Ihnen, wie Sie am besten vorgehen.

from Finanztip Feed
Supported by Video Collection
Share:

Finanzen: Rundfunkbeitrag – GEZ : Rundfunkbeitrag

Der Rundfunkbeitrag von 17,50 Euro im Monat ist verfassungsgemäß. Bei Zweitwohnungen unbedingt Antrag auf Befreiung stellen.

from Finanztip Feed
Supported by Video Collection
Share:

Insight into Cells that Convey Data from Eye to Brain

Insight into Cells that Convey Data from Eye to Brain


A team of researchers identified molecular differences between retinal ganglion cell subtypes, information which could lead to a better understanding as to why some respond differently to injury or treatments. The new study , published this week in Nature Communications , identifies 40 subtypes of retinal ganglion cells, which convey visual data from the eye to the brain, along with the genetic markers and transcription factors that differentiate them.



from Biotech News
Share:

Taconic Biosciences und Cyagen Biosciences geben strategische Partnerschaft bekannt

Taconic Biosciences und Cyagen Biosciences geben strategische Partnerschaft bekannt


Taconic Biosciences und Cyagen Biosciences, weltweit führende Anbieter anwendungsspezifischer gentechnisch veränderter Nagetiermodelle und damit verbundener Services kündigten eine strategische Partnerschaft an. Im Rahmen der Vertragsvereinbarungen werden die beiden Unternehmen ihre Ressourcen bünde...

from bionity.com News | Ein Übersichtsbeitrag über Goldankauf in Berlin, Germany.
Share:

Novartis übertrifft im zweiten Quartal Erwartungen

Novartis übertrifft im zweiten Quartal Erwartungen


(dpa) - Der Schweizer Pharmakonzern Novartis sieht sich dank seines Quartalsergebnisses auf Kurs. Besonders positiv schnitten die Bereiche Innovative Medizin mit einem Umsatzplus von zehn Prozent und die Augensparte Alcon (plus sieben Prozent Umsatz) ab. Die Augensparte soll im nächsten Jahr als eig...

from bionity.com News | Ein Übersichtsbeitrag über Goldankauf in Berlin, Germany.
Share:

ViiV Healthcare Shares Data from Landmark 2-Drug Regimen Trials At AIDS 2018

ViiV Healthcare Shares Data from Landmark 2-Drug Regimen Trials At AIDS 2018


Jul 18, 2018--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, will be presenting over 20 abstracts, including data from the landmark GEMINI 1 & 2 clinical trials, at the 22nd International AIDS Conference , 23-27 July 2018, in Amsterdam, The Netherlands. The data being presented this year has a strong focus on novel exploratory therapeutic options and innovative treatment strategies, as well as improving awareness and understanding of key issues that continue to affect the HIV community.



from Biotech News
Share:

NYSCF researchers develop novel bioengineering technique for personalized bone grafts

NYSCF researchers develop novel bioengineering technique for personalized bone grafts


Scientists from the New York Stem Cell Foundation Research Institute have developed a new bone engineering technique called Segmental Additive Tissue Engineering . The technique, described in a paper published online today in Scientific Reports , allows researchers to combine segments of bone engineered from stem cells to create large scale, personalized grafts that will enhance treatment for those suffering from bone disease or injury through regenerative medicine.



from Biotech News
Share:

Finanzen: Mietpreisbremse : Mietpreisbremse

In über 300 Städten müssen sich Vermieter bei einer Neuvermietung an die Mietpreisbremse halten. Mieter sollten ihre Rechte kennen und nicht jeden Mietpreis akzeptieren.

from Finanztip Feed
Supported by Video Collection
Share:

Novartis joins Pfizer in deferring drug-price hikes

Novartis joins Pfizer in deferring drug-price hikes


Novartis on Wednesday became the second major drug company to defer price increases in 2018, citing a "dynamic environment" in the U.S. as President Trump attempts to swat away critics and use market-based pressure to bring costs down. The Swiss company follows Pfizer Inc., which recently postponed price increases from July 1 to Jan. 1, prompting Mr. Trump to take a victory lap after he personally spoke to the CEO.



from Biotech News
Share:

Finanzen: Modernisierungsmaßnahmen in der Mietwohnung : Mieterhöhung nach Modernisierung

Steht eine Sanierung der Wohnung an, müssen sich Mieter auf Lärm, Dreck und eine höhere Miete einstellen. Der Vermieter muss die Baumaßnahmen aber ankündigen und darf bloße Reparaturkosten nicht auf den Mieter umlegen.

from Finanztip Feed
Supported by Video Collection
Share:

Finanzen: Betriebsrente : Betriebsrente

Mit einer Betriebsrente lässt sich die gesetzliche Rente aufbessern. Was Sie über Steuer, Krankenkasse, Kündigung und Todesfall wissen sollten.

from Finanztip Feed
Supported by Video Collection
Share:

Finanzen: Sinnvolle Versicherungen : Wichtige Versicherungen

Krankenversicherung und private Haftpflicht sind für jeden Verbraucher ein Muss. Manch andere Versicherung ist dagegen unnötig.

from Finanztip Feed
Supported by Video Collection
Share:

EU bereit zu Zöllen auf Pharma- und Chemieprodukte aus den USA

EU bereit zu Zöllen auf Pharma- und Chemieprodukte aus den USA


(dpa-AFX) - Die Europäische Union ist laut einem Pressebericht im Fall von US-Strafzöllen auf europäische Autos zu einem weitreichenden Gegenschlag bereit. Sollte die amerikanische Regierung unter Präsident Donald Trump Strafzölle auf Autos erheben, könnte die EU mit Zöllen auf amerikanische Pharma-...

from bionity.com News | Ein Übersichtsbeitrag über Goldankauf in Berlin, Germany.
Share:

Morphosys schließt Lizenzvereinbarung mit Novartis und erhöht Jahresprognose

Morphosys schließt Lizenzvereinbarung mit Novartis und erhöht Jahresprognose


(dpa-AFX) - Morphosys hat mit Novartis eine Lizenzvereinbarung für sein Wirkstoffprogramm MOR106 abgeschlossen. Dafür erhalten Morphosys und sein Entwicklungspartner Galapagos eine Vorauszahlung von 95 Millionen Euro, wie das Unternehmen am Donnerstag in Planegg mitteilte. Weitere Meilensteinzahlung...

from bionity.com News | Ein Übersichtsbeitrag über Goldankauf in Berlin, Germany.
Share:

Royal Bank of Canada Acquires 38,095 Shares of Alkermes Plc

Royal Bank of Canada Acquires 38,095 Shares of Alkermes Plc


Royal Bank of Canada boosted its holdings in Alkermes Plc by 104.2% during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 74,653 shares of the company's stock after acquiring an additional 38,095 shares during the quarter.



from Biotech News
Share:

Three charged with trespassing in Macomb

Three charged with trespassing in Macomb


State police on July 9 charged Terry D. Thomas, 35, of 202 Cedar St., Joseph J. Armstrong, 34, of 623 State St., both of Ogdensburg, and Justin E. Barbarito, 29, of 6812 County Route 10, Lisbon, each with a count of misdemeanor third-degree criminal trespass. Troopers charge at 4:11 p.m. at 6766 Route 58 in the town they responded to a report of a burglary after they said the property owner reported three motorcycles parked at the end of the driveway parallel to the roadway.



from Biotech News
Share:

Optische Kontrolle von Herzfrequenz oder Insulinsekretion durch lichtschaltbaren Wirkstoff

Optische Kontrolle von Herzfrequenz oder Insulinsekretion durch lichtschaltbaren Wirkstoff


Ionenkanäle sind porenbildende Proteinkomplexe, die einen Transport elektrisch geladener Teilchen über biologische Membranen ermöglichen. Sie erfüllen zentrale Aufgaben in der Physiologie jeder Zelle, von der Aufnahme und Ausscheidung von Stoffen bis zur Entstehung und Weiterleitung elektrischer Akt...

from bionity.com News | Ein Übersichtsbeitrag über Goldankauf in Berlin, Germany.
Share:

Johnson & Johnson wächst vor allem dank Pharmageschäft

Johnson & Johnson wächst vor allem dank Pharmageschäft


(dpa-AFX) Johnson & Johnson (J&J) hat auch im zweiten Quartal vor allem von seinem Pharmageschäft profitiert. Hinzu kamen auch günstige Wechselkurse. Wie der Hersteller von Medizintechnik, Konsumgütern und Pharmazeutika mitteilte, stieg der Umsatz im zweiten Quartal um 10,6 Prozent auf knapp 21 Mill...

from bionity.com News | Ein Übersichtsbeitrag über Goldankauf in Berlin, Germany.
Share:

Medicaid Under The Influence: How Drugmakers Sway Medication Options For Patients

Medicaid Under The Influence: How Drugmakers Sway Medication Options For Patients


Eight months pregnant, the drug sales representative wore a wire for the FBI around her bulging belly as she recorded conversations with colleagues at a conference in Chicago. Her code name? Pampers.



from Biotech News
Share:

Nanopartikel für lebensrettende Therapien

Nanopartikel für lebensrettende Therapien


Mit win­zi­gen Par­ti­keln Wirk­stoffe gezielt in erkrankte Organe des Kör­pers trans­por­tie­ren — die­sen Ansatz ver­folgt die Smart­Dye­Li­very GmbH aus Jena. Mit dem paten­tier­ten Kon­zept auf Basis funk­tio­na­li­sier­ter Nano­par­ti­kel konnte Smart­Dye­Li­very die Stif­tung für Tech­no­lo­gi...

from bionity.com News | Ein Übersichtsbeitrag über Goldankauf in Berlin, Germany.
Share:

Q4 2018 Earnings Forecast for Mylan NV Issued By Leerink Swann

Q4 2018 Earnings Forecast for Mylan NV Issued By Leerink Swann


Equities researchers at Leerink Swann decreased their Q4 2018 earnings per share estimates for shares of Mylan in a note issued to investors on Monday, July 16th. Leerink Swann analyst A. Fadia now anticipates that the company will earn $1.69 per share for the quarter, down from their previous estimate of $1.73.



from Biotech News
Share:

Chemical plant's neighbors to have blood, urine tested

Chemical plant's neighbors to have blood, urine tested


North Carolina and federal health officials want to test whether neighbors of a chemical company are carrying little-understood industrial compounds in their bodies. North Carolina's Department of Health and Human Services said Tuesday it is working with the U.S. Centers for Disease Control and Prevention and Bladen and Cumberland county health departments to test dozens of volunteers living around a Chemours Co.



from Biotech News
Share:

Volkskrankheit Rheumatoide Arthritis: Neue „Zielscheibe“ für nebenwirkungsarme Kortisontherapie

Volkskrankheit Rheumatoide Arthritis: Neue „Zielscheibe“ für nebenwirkungsarme Kortisontherapie


image description
Rheumatoide Arthritis ist eine Volkskrankheit - und oft werden die schmerzenden Gelenke mit kortisonhaltigen Medikamenten behandelt. Dabei reichen die Nebenwirkungen von Knochenschwund bis Diabetes. Eine Forschergruppe um Prof. Jan Tuckermann von der Universität Ulm hat nun molekulare Mechanismen de...

from bionity.com News | Ein Übersichtsbeitrag über Goldankauf in Berlin, Germany.
Share:

Finanzen: Mieterhöhung : Mieterhöhung

Wie oft und wie hoch – für Mieterhöhungen gelten klare Vorgaben. Hier finden Sie die wichtigsten Tipps für Mieter und Vermieter.

from Finanztip Feed
Supported by Video Collection
Share:

J&J Vows to Fight Verdict Linking Baby Powder to Ovarian Cancer

J&J Vows to Fight Verdict Linking Baby Powder to Ovarian Cancer


CEO and chairman Alex Gorsky vowed during a second-quarter earnings call on Tuesday, July 17, to fight a Missouri state court judgment handed down July 12 , in which 22 women were awarded $4.69 billion in a class action that alleged the company's talc-based baby powder products contained asbestos and caused them to develop ovarian cancer. Asbestos is a known carcinogen, according to the Centers for Disease Control and Prevention, and exposure to it can cause such life-threatening diseases as lung cancer, asbestosis and mesothelioma.



from Biotech News
Share:

Finanzen: Stromzähler : Stromzähler

Verbraucher bekommen in den nächsten Jahren digitale Stromzähler oder intelligente Messsysteme installiert. Das schreibt das Messstellenbetriebsgesetz vor. Für Haushalte bedeutet das höhere Kosten von bis zu 100 Euro pro Jahr.

from Finanztip Feed
Supported by Video Collection
Share:

Special relationship between UK and US scientists highlighted by adviser

Special relationship between UK and US scientists highlighted by adviser


Britain should "get very close" to the US from the perspective of science, the Government's new chief scientific adviser has said. Dr Patrick Vallance, previously head of Research and Development at pharmaceutical giants GlaxoSmithKline , stressed the importance of keeping science globally international as the Brexit deadline looms nearer.



from Biotech News
Share:

APEIRON gibt Wechsel des Vorstandsvorsitzenden bekannt

APEIRON gibt Wechsel des Vorstandsvorsitzenden bekannt


Das von dem bekannten österreichischen Molekularbiologen Josef Penninger gegründete Wiener Biotechnologie-Unternehmen APEIRON Biologics AG, das immun-onkologische Therapien gegen Krebs entwickelt, gab heute bekannt, dass Dr. Hans Loibner (70) nach fast 13 erfolgreichen Jahren sein Amt als Vorstandsv...

from bionity.com News | Ein Übersichtsbeitrag über Goldankauf in Berlin, Germany.
Share:

Merck ruft „Future Insight Prize“ für bahnbrechende wissenschaftliche Arbeiten ins Leben

Merck ruft „Future Insight Prize“ für bahnbrechende wissenschaftliche Arbeiten ins Leben


Merck hat einen neuen Forschungspreis ins Leben gerufen. Das Unternehmen wird den mit bis zu 1 Mio. € dotierten „Future Insight Prize“ über die kommenden 35 Jahre jährlich vergeben. Mit dem Preis ausgezeichnet werden Wissenschaftler, die außerordentliche Beiträge leisten, um für die Zukunft der Mens...

from bionity.com News | Ein Übersichtsbeitrag über Goldankauf in Berlin, Germany.
Share:

Per Anhalter zu einer besseren Wirkstoffabgabe

Per Anhalter zu einer besseren Wirkstoffabgabe


image description
Als Samir Mitragotri Ende der 1980er Jahre als Student an der Universität von Mumbai eintrat, gab es nur eine akademische Option für Studenten im Studiengang "Technologie": Chemieingenieurwesen. "Keiner von uns wusste, was Chemieingenieurwesen ist, als wir es studierten, und ich war mir ziemlich sic...

from bionity.com News | Ein Übersichtsbeitrag über Goldankauf in Berlin, Germany.
Share:

Rückruf von verunreinigten Blutdrucksenkern nahezu abgeschlossen

Rückruf von verunreinigten Blutdrucksenkern nahezu abgeschlossen


(dpa) - Nach dem Rückruf von bestimmten Blutdrucksenkern mit dem Wirkstoff Valsartan empfiehlt die zuständige Behörde eine Umstellung auf unbedenkliche Arzneimittel. Betroffene sollten mit ihrem Arzt oder Apotheker Rücksprache halten, welche Mittel von dem Rückruf betroffen sind, empfiehlt das Bunde...

from bionity.com News | Ein Übersichtsbeitrag über Goldankauf in Berlin, Germany.
Share:

Milliardenstrafe für Pharmakonzern Johnson & Johnson

Milliardenstrafe für Pharmakonzern Johnson & Johnson


(dpa) - Der US-Pharma- und Konsumgüterkonzern Johnson & Johnson (J&J) ist zu einer Milliardenstrafe verurteilt worden, weil bestimmte Körperpflegeprodukte Krebs verursacht haben sollen. Beim Prozess in St. Louis im US-Bundesstaat Missouri befand die Jury J&J einstimmig für schuldig und ordnete Schad...

from bionity.com News | Ein Übersichtsbeitrag über Goldankauf in Berlin, Germany.
Share:

Staatsanwaltschaft ermittelt gegen Pharmahändler in Brandenburg

Staatsanwaltschaft ermittelt gegen Pharmahändler in Brandenburg


(dpa) - Die Potsdamer Staatsanwaltschaft ermittelt wegen Hehlerei gegen eine Pharmafirma in Brandenburg. Die Ermittlungen liefen noch und seien nicht abgeschlossen, sagte Dorina Dubrau, Sprecherin der Staatsanwaltschaft Potsdam, am Freitag auf Anfrage. Weitere Details wollte die Sprecherin aus ermit...

from bionity.com News | Ein Übersichtsbeitrag über Goldankauf in Berlin, Germany.
Share:

US stocks rise as retailers and smaller companies climb

US stocks rise as retailers and smaller companies climb


After a weak start, U.S. indexes are higher Tuesday as retailers and smaller companies climb and investors applaud strong second-quarter results from health care products giant Johnson & Johnson and financial services company Charles Schwab. Netflix is plunging after the streaming video company gained fewer subscribers than Wall Street had hoped in its latest quarter and also projected weak results over the next three months.



from Biotech News
Share:

US stocks rise as retailers and smaller companies climb

US stocks rise as retailers and smaller companies climb


In this Dec. 21, 2016, file photo, the New York Stock Exchange is shown. The U.S. stock market opens at 9:30 a.m. EDT on Tuesday, July 17, 2018.



from Biotech News
Share:

Markets Right Now: Tech stocks lead US indexes lower

Markets Right Now: Tech stocks lead US indexes lower


Intel lost 1.4 percent early Tuesday. Netflix plunged 13 percent after reporting subscriber growth figures that missed its own estimates.



from Biotech News
Share:

Johnson & Johnson beats revenue, profit projections for 2Q

Johnson & Johnson beats revenue, profit projections for 2Q


Fueled by a 20 percent sales jump in its prescription drugs business, Johnson & Johnson posted a 3 percent increase in second-quarter profit. J&J's prescription medicine business, which had lagged its medical device business until a couple years ago, accounted for half its $20.83 billion in total revenue.



from Biotech News
Share:

Johnson & Johnson profit beat fueled by strength in pharma business

Johnson & Johnson profit beat fueled by strength in pharma business


FILE PHOTO: The Johnson and Johnson logo is seen at an office building in Singapore January 17, 2018. REUTERS/Thomas White Shares of the U.S. healthcare giant, which also trimmed its full-year sales forecast, were volatile in premarket trading.



from Biotech News
Share:

Teva's Skinny Label Found Not to Induce Infringement by Off-Label Use

Teva's Skinny Label Found Not to Induce Infringement by Off-Label Use


The US District Court for the District of Delaware granted in part Teva Pharmaceuticals' renewed motion for judgment as a matter of law , finding that substantial evidence did not support the jury's finding of induced infringement, and thus the jury's award of more than $235 million could not stand. GlaxoSmithKline LLC v.



from Biotech News
Share:

Finanzen: Kappungsgrenze : Kappungsgrenze bei Mieterhöhungen

Nicht jede Mieterhöhung ist zulässig. Mieter können sich oft gegen zu viel Miete zur Wehr setzen. Denn viele Vermieter missachten die Kappungsgrenze und verlangen überhöhte Beträge.

from Finanztip Feed
Supported by Video Collection
Share:

Blood pressure medicine made in China is recalled

Blood pressure medicine made in China is recalled


The Food and Drug Administration announced a voluntary recall of a widely prescribed blood pressure medication made in China, reviving fears about the safety of imported drugs. Three companies that sell the generic drug, valsartan, in the United States agreed to recall it after the FDA said might be tainted by N-nitrosodimethylamine , considered a probable human carcinogen.



from Biotech News
Share:

SeaWorld rescues, rehabilitates and returns Harbor seal to ocean

SeaWorld rescues, rehabilitates and returns Harbor seal to ocean


A harbor seal with the most severe neck wound that SeaWorld's rescue team had ever seen was returned to the ocean after undergoing rehabilitation at the San Diego theme park. The female seal was rescued from the La Jolla Children's Pool on June 29. A gill net embedded into the animal's neck was only centimeters from her vertebrae, according to Eric Otjen, SeaWorld's assistant curator of mammals.



from Biotech News
Share:

Finanzen: Indexfonds : ETF - Indexfonds

ETFs bilden Aktienindizes wie den Dax einfach nach. Sie sind günstig und brauchen wenig Pflege. Wir zeigen, worauf Sie achten müssen und wie Sie den geeigneten Indexfonds finden.

from Finanztip Feed
Supported by Video Collection
Share:

Urgent care centers often prescribe unnecessary antibiotics

Urgent care centers often prescribe unnecessary antibiotics


Patients with common colds and respiratory illnesses may be more likely to get antibiotics - which don't work for these conditions - when they go to an urgent care clinic, a U.S. study suggests. Overall, 39 percent of visits to urgent care centers resulted in antibiotic prescriptions, the study found.



from Biotech News
Share:

SPDR S&P Biotech (Xbi) Position Increased by Crescent Grove Advisors LLC

SPDR S&P Biotech (Xbi) Position Increased by Crescent Grove Advisors LLC


Crescent Grove Advisors LLC boosted its holdings in shares of SPDR S&P Biotech by 3.8% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 134,244 shares of the exchange traded fund's stock after purchasing an additional 4,917 shares during the quarter.



from Biotech News
Share:

US health official reveals fentanyl almost killed his son

US health official reveals fentanyl almost killed his son


The director of the Centers for Disease Control and Prevention says there's a personal reason for his focus on the opioid epidemic: His son almost died from taking fentanyl-laced cocaine. Dr. Robert Redfield Jr. called the opioid crisis "personal" in a speech to the National Association of County and City Health Officials.



from Biotech News
Share:

Reviewing Cellect Biotech/S

Reviewing Cellect Biotech/S


CELLECT BIOTECH/S and Cantel Medical are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, earnings, risk and institutional ownership. Cantel Medical has higher revenue and earnings than CELLECT BIOTECH/S.



from Biotech News
Share:

Fda Ok's first drug to treat smallpox, in case of terror attack

Fda Ok's first drug to treat smallpox, in case of terror attack


The smallpox vaccine helped eradicate the deadly illness, but a few samples of the virus were saved for research purposes. - a deadly disease that was wiped out four decades ago - in case the virus is used in a terror attack.



from Biotech News
Share:

Legal Experts See Obstacles for J&J Appeal of $4.7 Billion Talc Verdict

Legal Experts See Obstacles for J&J Appeal of $4.7 Billion Talc Verdict


Johnson & Johnson has vowed to appeal a $4.7 billion verdict awarded to 22 women who claim asbestos-contaminated talc in the company's products gave them ovarian cancer by arguing the plaintiffs' science was flawed and the case should not have been heard in Missouri. But several legal experts said that even though J&J has been successful in winning appeals of other talc cases in Missouri, it will face a challenging road in appealing the verdict handed down on Thursday in the Circuit Court of the City of St. Louis.



from Biotech News
Share:

Indivior shares surge on US court ruling

Indivior shares surge on US court ruling


Shares in pharmaceuticals group Indivior rocketed after a US court imposed a preliminary injunction on a rival firm selling or importing a generic version of one of its key drugs. Shares in pharmaceuticals group Indivior rocketed after a US court imposed a preliminary injunction on a rival firm selling or importing a generic version of one of its key drugs.



from Biotech News
Share:

Critical Contrast: Trinity Biotech

Critical Contrast: Trinity Biotech


Trinity Biotech and Myriad Genetics are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk and dividends. This is a breakdown of recent recommendations and price targets for Trinity Biotech and Myriad Genetics, as provided by MarketBeat.



from Biotech News
Share:

Adverum Biotechnologies (ADVM) versus Seattle Genetics (SGEN) Financial Survey

Adverum Biotechnologies (ADVM) versus Seattle Genetics (SGEN) Financial Survey


Adverum Biotechnologies and Seattle Genetics are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, risk, earnings, analyst recommendations and profitability. This is a breakdown of current ratings and recommmendations for Adverum Biotechnologies and Seattle Genetics, as provided by MarketBeat.com.



from Biotech News
Share:

Manning & Napier Group LLC Grows Position in Bristol-Myers Squibb Co

Manning & Napier Group LLC Grows Position in Bristol-Myers Squibb Co


Manning & Napier Group LLC boosted its holdings in Bristol-Myers Squibb Co by 17.4% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission . The fund owned 1,553,117 shares of the biopharmaceutical company's stock after purchasing an additional 230,707 shares during the quarter.



from Biotech News
Share:

Finanzen: Düsseldorfer Tabelle : Düsseldorfer Tabelle für 2018

Wenn Sie wissen möchten, wie viel Unterhalt Sie nach der Trennung oder Scheidung für die Kinder zahlen müssen, hilft Ihnen die aktuelle Düsseldorfer Tabelle.

from Finanztip Feed
Supported by Video Collection
Share:

Finanzen: Familienversicherung : Familienversicherung

Wer gesetzlich krankenversichert ist, kann seine Kinder und seinen Ehepartner kostenfrei mitversichern: Nur einer zahlt und die ganze Familie ist versichert.

from Finanztip Feed
Supported by Video Collection
Share:

Morgan Stanley Lowers Biogen (BIIB) Price Target to $366.00

Morgan Stanley Lowers Biogen (BIIB) Price Target to $366.00


The brokerage currently has an "overweight" rating on the biotechnology company's stock. Morgan Stanley's target price would indicate a potential upside of 5.03% from the stock's current price.



from Biotech News
Share:

Traders Sell SPDR S&P Biotech

Traders Sell SPDR S&P Biotech


Investors sold shares of SPDR S&P Biotech on strength during trading on Thursday. $62.20 million flowed into the stock on the tick-up and $139.96 million flowed out of the stock on the tick-down, for a money net flow of $77.76 million out of the stock.



from Biotech News
Share:

Merck & Co., Inc. (MRK) Shares Sold by Blair William & Co. IL

Merck & Co., Inc. (MRK) Shares Sold by Blair William & Co. IL


Blair William & Co. IL decreased its holdings in shares of Merck & Co., Inc. by 5.0% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission .



from Biotech News
Share:

Head to Head Comparison: Nymox Pharmaceutical

Head to Head Comparison: Nymox Pharmaceutical


Nymox Pharmaceutical and Neogen are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, profitability, dividends, institutional ownership, valuation, earnings and analyst recommendations. Nymox Pharmaceutical has a beta of 0.7, indicating that its stock price is 30% less volatile than the S&P 500.



from Biotech News
Share:

Correction: Talc Powder-Cancer Lawsuit story

Correction: Talc Powder-Cancer Lawsuit story


In a story on July 12 about a jury ruling on claims that asbestos in Johnson & Johnson talcum powder contributed to ovarian cancer, The Associated Press erroneously reported that the case was the first against the company that focused on asbestos in the powder. Other lawsuits have alleged asbestos in the powder contributed to cancer.



from Biotech News
Share:

What To Make Of Johnson & Johnson's $4.7 Billion Verdict For Talc Products

What To Make Of Johnson & Johnson's $4.7 Billion Verdict For Talc Products


Johnson Johnson was recently ordered by a jury in Missouri to pay $550m in compensation and an additional $4.14 billion in punitive damages, in a case related to its talc products. The company was previously able to get a relief in a similar case last year, where a woman alleged that she developed ovarian cancer after using JJ's talc products, and it will be interesting to see if the company gets a similar relief in this case, given it plans to appeal the verdict.



from Biotech News
Share:

Why J&J Investors Aren't So Concerned About $4.69B Talc Verdict

Why J&J Investors Aren't So Concerned About $4.69B Talc Verdict


Johnson & Johnson should ready itself for a flood of new lawsuits after a jury ordered the company to pay $4.69 billion to 22 women who blamed their ovarian cancer on asbestos in its talc products, legal experts said.



from Biotech News
Share:

Friday Wake-Up Call: J&J's huge payout, Olson resigns Papa John's, our Trump dump and more

Friday Wake-Up Call: J&J's huge payout, Olson resigns Papa John's, our Trump dump and more


Welcome to Ad Age's Wake-Up Call, our daily roundup of advertising, marketing, media and digital news. You can get an audio version of this briefing on your Alexa device.



from Biotech News
Share:

Will the $4.7 Billion Talc Verdict Hold Up On Appeal?

Will the $4.7 Billion Talc Verdict Hold Up On Appeal?


The nearly $4.7 billion verdict that a St. Louis jury handed down Thursday against Johnson & Johnson over its talcum powder was by far the largest verdict seen out of a litigation that has already produced several eye-catching wins for plaintiffs. Max Mitchell is a reporter with The Legal Intelligencer, focusing on litigation in Pennsylvania with a specific emphasis on Philadelphia courts.



from Biotech News
Share:

FDA OKs 1st drug to treat smallpox, in case of terror attack

FDA OKs 1st drug to treat smallpox, in case of terror attack


On Friday, July 13, 2018, U.S. regulators announced the approval of the first treatment for small... . This undated photo provided by SIGA in July 2018 shows capsules of the drug TPOXX.



from Biotech News
Share:

FDA OKs 1st drug to treat smallpox, in case of terror attack

FDA OKs 1st drug to treat smallpox, in case of terror attack


On Friday, July 13, 2018, U.S. regulators announced the approval of the first treatment for small... . This undated photo provided by SIGA in July 2018 shows capsules of the drug TPOXX.



from Biotech News
Share:

FDA OKs 1st drug to treat smallpox, in case of terror attack

FDA OKs 1st drug to treat smallpox, in case of terror attack


U.S. regulators Friday approved the first treatment for smallpox - a deadly disease that was wiped out four decades ago - in case the virus is used in a terror attack. But people born since then haven't been vaccinated, and small samples of the smallpox virus were saved for research purposes, leaving the possibility it could be used as a biological weapon.



from Biotech News
Share:

Press release distribution, EDGAR filing, XBRL, regulatory filings

Press release distribution, EDGAR filing, XBRL, regulatory filings


The company will host a conferen... )--Home Capital Group Inc. will report financial results for the three months and six months ended June 30, 2018 on Monday, Augus... )--The global friction stir welding equipment market is expected to post a CAGR of close to 10% during the period 2018-2022, according to Technavio. )--In the past decade, there have been frequent reports about the decline in sports participation.



from Biotech News
Share:

Man, 23, arrested at GSK factory after police search

Man, 23, arrested at GSK factory after police search


Officers from Durham Police are searched the GlaxoSmithKline site, in Barnard Castle , after they discovered the man in a vehicle just before 9am.



from Biotech News
Share:

La Jolla: Outrage at diver spotted killing stingrays

La Jolla: Outrage at diver spotted killing stingrays


LA JOLLA A disturbing case of animal torture off La Jolla Shores was captured on camera. Photographs show a man stabbing stingrays to death for no apparent reason.



from Biotech News
Share:

Mother arrested on manslaughter charge in 2-year-old son's death

Mother arrested on manslaughter charge in 2-year-old son's death


Douglas County Sheriff's Office detectives arrested a 35-year-old Wenatchee woman Wednesday after in connection to the death of her 2-year-old son. The Sheriff's Office says the arrest comes after an extensive investigation.



from Biotech News
Share:

'Do not eat this cereal': CDC links Honey Smacks, salmonella

'Do not eat this cereal': CDC links Honey Smacks, salmonella


The Centers for Disease Control and Prevention says a popular Kellogg's cereal has been linked to a salmonella outbreak that has infected 100 people in 33 states. The CDC announced Thursday that customers should avoid Honey Smacks, tweeting, "Do not eat this cereal."



from Biotech News
Share:

$550 million awarded in lawsuit linking cancer, baby powder

$550 million awarded in lawsuit linking cancer, baby powder


Nearly two dozen women who claimed asbestos in Johnson & Johnson talcum powder caused their ovarian cancer were awarded $550 million in damages Thursday by a St. Louis jury in the first case against the company that focused on asbestos in the powder. Punitive damages are still to be decided for the 22 plaintiffs in a case that began June 4 in St. Louis Circuit Court.



from Biotech News
Share:

Novartis beendet Forschung zu Infektionskrankheiten

Novartis beendet Forschung zu Infektionskrankheiten


(dpa-AFX) Der Pharmakonzern Novartis verabschiedet sich aus der Forschung zu Infektionskrankheiten. Dem Rückzug sollen laut einem Bericht der Nachrichtenagentur Bloomberg 140 Stellen an der amerikanischen Westküste zum Opfer fallen. Die Ankündigung des Basler Pharmariesen reiht sich ein in den Branc...

from bionity.com News | Ein Übersichtsbeitrag über Goldankauf in Berlin, Germany.
Share:

EXIST-Förderung für Ausgründungsvorhaben „Tetra-Tag“

EXIST-Förderung für Ausgründungsvorhaben „Tetra-Tag“


image description
Das Bundesministerium für Wirtschaft und Energie, der Europäische Sozialfonds und die Europäische Union fördern das Gründungsvorhaben „Tetra-Tag“ mit einem EXIST-Gründerstipendium. Die Chemiker Dr. Fabian Ehret und Dr. Vasileios Filippou sowie der Wirtschaftswissenschaftler Patrick Metzger erhalten ...

from bionity.com News | Ein Übersichtsbeitrag über Goldankauf in Berlin, Germany.
Share:

Chemisch-pharmazeutische Industrie mit sorgenvollem Ausblick

Chemisch-pharmazeutische Industrie mit sorgenvollem Ausblick


image description
Die Geschäfte der chemisch-pharmazeutischen Industrie verliefen im ersten Halbjahr 2018 erfreulich, aber die Perspektive für den Rest des Jahres ist verhaltener. Wie der Verband der Chemischen Industrie (VCI) in seiner Halbjahresbilanz berichtet, erhöhte sich der Umsatz von Januar bis Juni 2018 im V...

from bionity.com News | Ein Übersichtsbeitrag über Goldankauf in Berlin, Germany.
Share:

The Latest: Jury awards nearly $4.7 billion in powder case

The Latest: Jury awards nearly $4.7 billion in powder case


The Latest on a St. Louis jury award in a lawsuit claiming asbestos in Johnson & Johnson talcum powder caused women's ovarian cancer : A St. Louis jury has awarded nearly $4.7 billion in damages to 22 women and their families after they claimed asbestos in Johnson & Johnson talcum powder caused their ovarian cancer. Jurors on Thursday awarded the women $4.14 billion in punitive damages and $550 million in compensatory damages after a six-week trial in St. Louis Circuit Court.



from Biotech News
Share:

Goldman Sachs Swaps Perrigo, Johnson & Johnson Ratings

Goldman Sachs Swaps Perrigo, Johnson & Johnson Ratings


The iShares Dow Jones US Healthcare is up marginally year-to-date, but the profits aren't bleeding into all health care constituents. Goldman Sachs analyst Jami Rubin upgraded Johnson & Johnson from Sell to Neutral and maintained a $134 price target.



from Biotech News
Share:

Sen. Claire McCaskill, D-Mo., during a hearing in Washington on Sept. 27, 2017.

Sen. Claire McCaskill, D-Mo., during a hearing in Washington on Sept. 27, 2017.


Registration will allow you to post comments on newstimes.com and create a newstimes.com Subscriber Portal account for you to manage subscriptions and email preferences. WASHINGTON - Three companies shipped approximately 1.6 billion doses of powerful prescription opioids to Missouri pharmacies from 2012 to 2017, according to a congressional report seeking the root causes of the opioid epidemic.



from Biotech News
Share:

Short Interest in Navidea Biopharmaceuticals Inc (NAVB) Expands By 2.2%

Short Interest in Navidea Biopharmaceuticals Inc (NAVB) Expands By 2.2%


Navidea Biopharmaceuticals Inc was the target of a significant growth in short interest during the month of June. As of June 29th, there was short interest totalling 5,310,973 shares, a growth of 2.2% from the June 15th total of 5,197,443 shares.



from Biotech News
Share:

Trial begins this month for Pittsfield businessman accused of bilking investors out of $400K

Trial begins this month for Pittsfield businessman accused of bilking investors out of $400K


Muraca is accused of defrauding investors in a pair of biotech companies he founded by using about $400,000 of their seed money for personal expenses wholly unrelated to the running of those businesses; Muraca had told investors their money would be used for pharmaceutical development and commercialization, according to the complaint. Some investor money was deposited directly into Muraca's personal account, according to the complaint.



from Biotech News
Share:

Pfizer baut Organisation um

Pfizer baut Organisation um


(dpa-AFX) Der US-Pharmariese Pfizer will umbauen und sich künftig in drei Sparten aufstellen. Ab dem Geschäftsjahr 2019 gehören zur forschenden Sparte neuartige Medikamente und sogenannte Biosimilars, wie Pfizer am Mittwoch in New York mitteilte. Das Geschäft soll in einem neuen Bereich auch Kranken...

from bionity.com News | Ein Übersichtsbeitrag über Goldankauf in Berlin, Germany.
Share:

Gerresheimer gewinnt Großaufträge und baut Geschäft mit Übernahme aus

Gerresheimer gewinnt Großaufträge und baut Geschäft mit Übernahme aus


(dpa-AFX) Großaufträge stimmen den Verpackungsspezialisten Gerresheimer mittelfristig optimistischer. Zudem soll das Produktangebot durch die Übernahme eines Medizintechnikherstellers ausgebaut werden. Auch schon für 2018 gibt sich der Konzern in Erwartung eines starken zweiten Halbjahres etwas zuve...

from bionity.com News | Ein Übersichtsbeitrag über Goldankauf in Berlin, Germany.
Share:

Finanzen: KfW Umbauen : KfW 455

Wer altersgerecht umbaut, Barrieren reduziert und den Einbruchschutz verbessert, kann Förderung bei der KfW beantragen.

from Finanztip Feed
Supported by Video Collection
Share:

Finanzen: KfW energieeffizient sanieren : KfW 430

Wer Haus oder Wohnung energetisch saniert, sollte die Förderungen der KfW kennen. Es winken günstige Kredite und Zuschüsse.

from Finanztip Feed
Supported by Video Collection
Share:

Finanzen: KfW Förderung : KfW Förderung - Bauförderung und Kredit

Die staatliche Förderbank KfW finanziert Haus oder Wohnung, das Studium oder die Existenzgründung. Verbraucher sollten die Möglichkeiten kennen

from Finanztip Feed
Supported by Video Collection
Share:

Clinical trial results of tucatinib with T-DM1 shows promise in treating HER2+ breast cancer

Clinical trial results of tucatinib with T-DM1 shows promise in treating HER2+ breast cancer


Phase 1b clinical trial results published in JAMA Oncology show promise for the combination of tucatinib with T-DM1 against heavily pretreated HER2-positive breast cancer. Of 57 patients treated, 48 percent responded to the combination, with cancer control of median 8.2 months.



from Biotech News
Share:

ASX advances on bank strength as CSL breaks $200

ASX advances on bank strength as CSL breaks $200


The Australian sharemarket closed higher on Thursday despite an overnight commodity plunge that saw Brent crude prices record their biggest fall in two years. The S&P/ASX 200 index advanced 52.7 points, or 0.9 per cent, to 6268.3, shaking off the trade fears that have rattled the benchmark index in the past two sessions.



from Biotech News
Share:

Trinity Biotech (TRIB) Set to Announce Earnings on Wednesday

Trinity Biotech (TRIB) Set to Announce Earnings on Wednesday


Trinity Biotech will be posting its quarterly earnings results on Wednesday, July 18th. Analysts expect Trinity Biotech to post earnings of $0.06 per share for the quarter.



from Biotech News
Share:

Most actively traded companies on the TSX

Most actively traded companies on the TSX


Bombardier Inc. . Aerospace, rail equipment. Up three cents, or 0.56 per cent, to $5.43 on 14.3 million shares.



from Biotech News
Share:

SPDR S&P Biotech (Xbi) Shares Bought by Winfield Associates Inc.

SPDR S&P Biotech (Xbi) Shares Bought by Winfield Associates Inc.


Winfield Associates Inc. increased its holdings in shares of SPDR S&P Biotech by 22.2% in the second quarter, according to its most recent filing with the SEC. The fund owned 29,400 shares of the exchange traded fund's stock after acquiring an additional 5,335 shares during the period.



from Biotech News
Share:

Pfizer stock dips as Trump says Pfizer CEO agreed to drop drug price hikes

Pfizer stock dips as Trump says Pfizer CEO agreed to drop drug price hikes


"Pfizer is rolling back price hikes, so American patients don't pay more," Trump said in a tweet that mentioned a meeting with Pfizer Chief Executive Ian Read and Health and Human Services Secretary Alex Azar. "We applaud Pfizer for this decision and hope other companies do the same."



from Biotech News
Share:

Trump says Pfizer is rolling back drug price hikes

Trump says Pfizer is rolling back drug price hikes


FILE PHOTO: The Pfizer logo is seen at their world headquarters in Manhattan, New York, U.S., August 1, 2016. REUTERS/Andrew Kelly Pfizer said it would defer price increases that went into effect on July 1 until the end of the year or until the president's drug pricing blueprint goes into effect - whichever is sooner.



from Biotech News
Share:

Zu hoher Schadstoff-Ausstoß: Pharma-Fabrik in Frankreich geschlossen

Zu hoher Schadstoff-Ausstoß: Pharma-Fabrik in Frankreich geschlossen


(dpa) Wegen drastisch erhöhter Schadstoff-Emissionen hat der Pharmakonzern Sanofi eine seiner Fabriken in Frankreich vorübergehend geschlossen. Die Produktionsstätte in Mourenx nahe der Pyrenäen dürfe erst wieder öffnen, wenn «alle Voraussetzungen bezüglich der Emissionen sowie der Risiken für die A...

from bionity.com News | Ein Übersichtsbeitrag über Goldankauf in Berlin, Germany.
Share:

Takeda bekommt in den USA Zustimmung zu Shire-Übernahme

Takeda bekommt in den USA Zustimmung zu Shire-Übernahme


(dpa-AFX) Der japanische Pharmakonzern Takeda hat eine wichtige Hürde für die geplante milliardenschwere Übernahme seines irischen Rivalen Shire genommen. Die Handelskommission (FTC) der USA habe dem Deal ohne Auflagen zugestimmt, teilte Takeda am Dienstag in Osaka mit. Allerdings stehe noch die Gen...

from bionity.com News | Ein Übersichtsbeitrag über Goldankauf in Berlin, Germany.
Share:

Pfizer will nach Trump-Kritik Preiserhöhungen aussetzen

Pfizer will nach Trump-Kritik Preiserhöhungen aussetzen


(dpa) Der Pharmariese Pfizer will nach heftiger Kritik von US-Präsident Donald Trump bestimmte Preiserhöhungen für Arzneimittel aussetzen. Nach «ausführlichen Diskussionen» mit Trump habe man sich entschlossen, dem Präsident zunächst die Gelegenheit zu geben, an seinem Plan zur Stärkung des Gesundhe...

from bionity.com News | Ein Übersichtsbeitrag über Goldankauf in Berlin, Germany.
Share:

Under pressure from Trump, Pfizer delays drug price increases

Under pressure from Trump, Pfizer delays drug price increases


Pfizer chief executive Ian Read said late Tuesday his company would delay increasing the prices on dozens of drug products after President Donald Trump publicly berated the firm one day earlier. The company, in a statement, said the price increases would effectively be postponed at least until the beginning of 2019 in order "to give the president an opportunity to work on his blueprint to strengthen the healthcare system and provide more access to patients."



from Biotech News
Share:

Large-cap biotech stocks will just tread water as sector sizzles

Large-cap biotech stocks will just tread water as sector sizzles


That's the advice from analysts covering the sector as shares of companies such as Celgene Corp. and Regeneron Pharmaceuticals Inc. have failed to keep pace with their smaller rivals over the past six months. Even as the Nasdaq Biotech Index rose for a seventh straight day on Monday, its longest streak since March, analysts don't expect the largest names in the group will see a sustained rebound in the second half of the year.



from Biotech News
Share:

Seth Klarman Declares Ownership of Fledgling Biotech

Seth Klarman Declares Ownership of Fledgling Biotech


Translate Bio is developing a drug to treat cystic fibrosis. The drug received orphan designation in 2015 and is undergoing clinical trial Seth Klarman has declared 14.5% interest in a Massachusetts-based startup that is working on a new drug to treat cystic fibrosis, which affects more than 70,000 people in the world.



from Biotech News
Share:

Hologic, Inc. (HOLX) Receives Consensus Rating of "Hold" from Brokerages

Hologic, Inc. (HOLX) Receives Consensus Rating of "Hold" from Brokerages


Shares of Hologic, Inc. have been assigned a consensus rating of "Hold" from the eighteen research firms that are presently covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a sell rating, six have issued a hold rating and nine have assigned a buy rating to the company.



from Biotech News
Share:

4,000 Shares in Biogen Inc (BIIB) Acquired by Polianta Ltd

4,000 Shares in Biogen Inc (BIIB) Acquired by Polianta Ltd


Polianta Ltd purchased a new stake in shares of Biogen Inc during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 4,000 shares of the biotechnology company's stock, valued at approximately $1,160,000.



from Biotech News
Share:

Upbeat Celgene Data Not Enough to Lift Biotech Sector

Upbeat Celgene Data Not Enough to Lift Biotech Sector


Shares of Celgene and Acceleron Pharma are climbing on Tuesday, after announcing that Luspatercept, the anemia drug the biotech firms are jointly developing, performed well in a Phase III study. The news isn't entirely a surprise, as analysts were expecting positive results, due to data from a previous study that supported the drug's chances of success.



from Biotech News
Share:

Tennessee gets $4.3M federal grant for student health

Tennessee gets $4.3M federal grant for student health


Tennessee is receiving a federal grant of more than $4.3 million to help prevent student obesity, manage childhood chronic disease and prevent those sicknesses in adulthood. According to the state Department of Education, the grant from the Centers for Disease Control and Prevention will focus on awareness and policies for school-based health education, physical education and physical activity, healthy eating, and management of chronic health conditions.



from Biotech News
Share:

NIH: Teen drivers 8 times more likely to crash shortly after...

NIH: Teen drivers 8 times more likely to crash shortly after...


A new study, led by the National Institutes of Health, shows teen drivers are eight times more likely to be involved in a crash in the first three months after getting their license, compared to the first three months after gettign their learner's permit. less A new study, led by the National Institutes of Health, shows teen drivers are eight times more likely to be involved in a crash in the first three months after getting their license, compared to ... more A new study validates the fears of every parent who has logged multiple sleepless nights after a child has earned his or her driver's license.



from Biotech News
Share:

France launches 100 million euros biotech fund

France launches 100 million euros biotech fund


The French government has agreed to launch a 100 million euros fund aimed at promoting early-stage biotechnology companies, Prime Minister Edouard Philippe said on Tuesday. French state bank BpiFrance will contribute 50 million euros to the venture with drugmaker Sanofi committing to another 50 million, the government said, adding the size of the fund could then reach some 250 million euros depending on interest expressed by other potential investors.



from Biotech News
Share:

Finanzen: Entgeltumwandlung : Entgeltumwandlung

Entgeltumwandlung (Gehaltsumwandlung) bedeutet, dass Sie Teile Ihres Gehalts in eine betriebliche Altersvorsorge (bAV) stecken. Steuern und Abgaben entfallen.

from Finanztip Feed
Supported by Video Collection
Share:

Takeda gets key U.S. regulatory approval to buy Shire

Takeda gets key U.S. regulatory approval to buy Shire


Japan's Takeda Pharmaceutical Co Ltd said on Tuesday it received a key U.S. regulatory approval for its $62 billion deal to buy London-listed Shire Plc .



from Biotech News
Share:

Press release distribution, EDGAR filing, XBRL, regulatory filings

Press release distribution, EDGAR filing, XBRL, regulatory filings


Celgene and Acceleron Announce Luspatercept Achieved Primary and All Key Secondary Endpoints in Phase III 'BELIEVE' Study in Adults with Transfusion-Dependent Beta-Thalassemia )--Celgene Corporation and Acceleron Pharma Inc. today announced results from a phase III, randomized, double-blind, mul... )--Harris Williams & Co., a preeminent middle market investment bank focused on the advisory needs of clients worldwide for more than 25 years, announces that it ad... )--Ajax Health , a privately held clinical-stage platform company focused on developing medical technologies, announced today the closing of an oversubscri... )--Cactus, Inc. announced today that it has commenced an underwritten public offering of 10,000,000 shares of its Class A common stock... )--Shionogi & Co., Ltd. has announced that effective... )--Ares Management, L.P. announced today that it will report earnings for the ... (more)



from Biotech News
Share:

Finanzen: Betriebliche Altersvorsorge : Betriebliche Altersvorsorge

Betriebliche Altersvorsorge ist eine Möglichkeit für Arbeitnehmer, die gesetzliche Rente im Alter aufzustocken. Zahlen Mitarbeiter Beiträge aus ihrem Bruttogehalt, sparen sie sich die Sozialabgaben und Steuern.

from Finanztip Feed
Supported by Video Collection
Share:

Genome editing reduces cholesterol in large animal model, laying human trial groundwork

Genome editing reduces cholesterol in large animal model, laying human trial groundwork


Using genome editing to inactivate a protein called PCSK9 effectively reduces cholesterol levels in rhesus macaques, a species of monkey, according to researchers from the Perelman School of Medicine at the University of Pennsylvania. This is the first demonstration of a clinically relevant reduction of gene expression in a large animal model using genome editing.



from Biotech News
Share:

Michael Amoroso to Join Kite as Senior Vice President and Head of Worldwide Commercial, Cell Therapy

Michael Amoroso to Join Kite as Senior Vice President and Head of Worldwide Commercial, Cell Therapy


In this position, Mr. Amoroso will have responsibility for Kite's commercial organization including sales, marketing, market access, and healthcare provider and patient services. Mr. Amoroso will begin his new role in August, reporting to John F. Milligan, PhD, President and Chief Executive Officer of Gilead, and will become a member of the Kite Cell Therapy Leadership Team.



from Biotech News
Share:

Trump Attacks Pfizer Over Drug Prices in Latest Dig at Industry

Trump Attacks Pfizer Over Drug Prices in Latest Dig at Industry


President Donald Trump said Pfizer Inc. should be "ashamed" for raising the prices of its pharmaceutical products, rattling shares of the U.S. drug giant on Monday. tweet .



from Biotech News
Share: